# **U.S. PRODUCERS' QUESTIONNAIRE**

## CALCIUM HYPOCHLORITE FROM CHINA

#### This questionnaire must be received by the Commission by no later than JANUARY 2, 2014

#### See the Instruction Booklet for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its countervailing duty and antidumping investigations concerning calcium hypochlorite ("calhypo") from China (Inv. Nos. 701-TA-510 and 731-TA-1245 (Preliminary)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

Name of fi	rm		
			Zip Code
World Wi	de Web address		
Has your fir	m produced calhypo (as defined in the	e instruction bo	ooklet) at any time since January 1, 2010?
<b>NO</b>	(Sign the certification below and pron	nptly return only	this page of the questionnaire to the Commission)
<b>YES</b>	(Read the instruction booklet carefully questionnaire to the Commission so as		arts of the questionnaire, and return the entire by the date indicated above)
			ade Commission <i>Drop Box</i> by clicking <u>/</u> . (use the following PIN: HYPO)

## CERTIFICATION

I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge and belief and understand that the information submitted is subject to audit and verification by the Commission.

By means of this certification I also grant consent for the Commission, and its employees and contract personnel, to use the information provided in this questionnaire and throughout this proceeding in any other import-injury proceedings conducted by the Commission on the same or similar merchandise.

I acknowledge that information submitted in this questionnaire response and throughout this proceeding may be used by the Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or maintaining the records of this proceeding or related proceedings for which this information is submitted, or in internal audits and proceedings relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all contract personnel will sign non-disclosure agreements.

Name of Authorized Official	Title of Authorized Official	Date	
	Phone:		
Signature		Email address	
	<i>Fax:</i>		

### PART I.—<u>GENERAL INFORMATION</u>

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

I-1a. <u>**OMB statistics**</u>.--Please report below the actual number of hours required and the cost to your firm of preparing the reply to this questionnaire and completing the form.

Hours	Dollars			

- I-1b. <u>**OMB feedback**</u>.--We are interested in any comments you may have for improving this questionnaire in general or the clarity of specific questions. Please attach such comments to your firm's response or send them to the above address.
- I-2. **Establishments covered**.--Provide the name and address of establishment(s) covered by this questionnaire (see page 3 of the instruction booklet for reporting guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol.

#### I-3. <u>Petition support</u>.--Does your firm support or oppose the petition?

Country	Support	Oppose	Take no position
China			

### PART I.--GENERAL INFORMATION--Continued

I-4. **Ownership**.--Is your firm owned, in whole or in part, by any other firm?

Yes--List the following information.

Firm name	Address	Extent of ownership ( <i>percent</i> )

- I-5. <u>**Related importers/exporters.**</u>--Does your firm have any related firms, either domestic or foreign, that are engaged in importing calhypo from China into the United States or that are engaged in exporting calhypo from China to the United States?
  - No Yes--List the following information.

Firm name	Address	Affiliation

I-6. **<u>Related producers</u>**.--Does your firm have any related firms, either domestic or foreign, that are engaged in the production of calhypo?

No Yes--List the following information.

Firm name	Address	Affiliation

# PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Joanna Lo (202-205-1888, joanna.lo@usitc.gov). Supply all data requested on a <u>calendar-year</u> basis.

II-1. <u>Contact information</u>.-- Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in part II.

Name	
Title	
Email	
Telephone	
Fax	

II-2. <u>Changes in operations</u>.--Please indicate whether your firm has experienced any of the following changes in relation to the production of calhypo since January 1, 2010.

(che	ck as many as appropriate)	(please describe)
$\square$	plant openings	
	1 1 2	
	plant closings	
	relocations	
	expansions	
	exputitions	
	acquisitions	
_		
	consolidations	
	prolonged shutdowns or	
	production curtailments	
	-	
	other $(\rho, q)$ technology)	
	outer (e.g., technology)	

# PART II.--<u>TRADE AND RELATED INFORMATION</u>--Continued

<u>Same equipment, machinery, and workers</u> Has your firm since 2010 produced, or does your firm anticipate producing in the future, other products on the same equipment and machinery used in the production of calhypo and/or using the same production and related workers employed to produce calhypo?								
No YesList the following information and report your firm's combined production capacity and production of these products and calhypo in the periods indicated.								
Product 1		<u>eriod</u>		<b>Basis for allocation of capacity and</b> employment data (indicate if different)				
		(Quantity i	n 1,000 poun	ds)				
		-	-	alendar years		September		
Item Overall Production Capa	oity	2010	2011	2012	2012	2013		
Production of: calhypo	спу							
Other product 1:								
Other product 2:								
Production constraints         on your firm's production	n capacity 1, 2010, ł ) regardin	y and its abilit	ty to shift pro	ed in a toll agr	city between	products.		
<b>Foreign trade zone</b> Do	-	firm produce of FTZ(s):		-				
ImporterSince Januar								
No Yes	<u>COMPL</u>	ETE AND R	<u>ETURN A L</u>	.S. IMPORT	ERS' QUES	<u>FIONNAL</u>		

# Page 6

### PART II.--<u>TRADE AND RELATED INFORMATION</u>--Continued

II-8. <u>**Trade data</u>**.--Report your firm's production capacity, production, shipments, inventories, and employment related to the production of calhypo in its U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)</u>

	Calendar years			January-September	
Item	2010 2011		2012	2012	2013
Average production capacity <sup>1</sup> (quantity)					
Beginning-of-period inventories (quantity)					
Production (quantity)					
U.S. shipments: Commercial shipments: Quantity of commercial shipments					
Value of commercial shipments					
Internal consumption: Quantity of internal consumption					
Value <sup>2</sup> of internal consumption					
Transfers to related firms: Quantity of transfers					
Value <sup>2</sup> of transfers					
Export shipments: <sup>3</sup> Quantity of export shipments					
Value of export shipments					
End-of-period inventories <sup>4</sup> (quantity)					
Channels of distribution: U.S. shipments to distributors (quantity)					
U.S. shipments to end users (quantity)					
Employment data: Average number of PRWs (number)					
Hours worked by PRWs (1,000 hours)					
Wages paid to PRWs (value)					
<sup>1</sup> The production capacity (see definitions in in weeks per year. Please describe the met reported capacity (use additional pages as nece	hodology used t				

<sup>3</sup> Identify your firm's principal export markets: \_

<sup>4</sup> Reconciliation of data.--Please note that the **quantities** reported above should reconcile as follows: beginning-of-period inventories, plus production, less total shipments, equals end-of-period inventories. Do the data reported reconcile?

Yes No--Please explain:

# PART II.--<u>TRADE AND RELATED INFORMATION</u>--Continued

II-9.	<b><u>Related firms</u></b> If your firm reported transfers to related firms in question II-8, please indicate the nature of the relationship between your firm and the related firms ( <i>e.g.</i> , joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formul whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.								
II-10.	Purchases.      Other than direct imports, has your firm otherwise purchased calhypo since Janu 1, 2010? (See definitions in the instruction booklet.)         No       YesReport such purchases below for the specified periods. <sup>1</sup>								
	(Quantity		<i>nds</i> , value <i>in</i> Calendar yeai	-	lanuary-9	September			
	ltem	2010	2011	2012	2012	2013			
OF CA Chir	Quantity								
All o	Value other countries: Quantity								
PURCI PROD	Value HASES FROM DOMESTIC UCERS: <sup>2</sup> antity								
Val	-								
-	HASES FROM OTHER SOURCES: <sup>2</sup> lantity								
Val	ue								
<sup>1</sup> Pl elabora	ease indicate your firm's reasons for p ate.	urchasing this	s product. If y	our firm's reas	sons differ by se	ource, please			
	ease list the name of the firm(s) from v rce, please identify the source for each			nis product. If	f your firm's sup	opliers differ			

#### PART III.--FINANCIAL INFORMATION

Address questions on this part of the questionnaire to David Boyland (202-708-4725, David.Boyland@usitc.gov).

III-1. <u>Contact information</u>.-- Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in part III.

Name	
Title	
Email	
Telephone	
Fax	

- III-2. Accounting system.--Briefly describe your firm's financial accounting system.
  - A. When does your firm's fiscal year end (month and day)? \_\_\_\_\_\_\_ If your firm's fiscal year changed during the data-collection period, explain below:
  - B.1. Describe the lowest level of operations (e.g., plant, division, company-wide) for which financial statements are prepared that include calhypo:
    - 2. Does your firm prepare profit/loss statements for the calhypo: ☐ Yes ☐ No
    - 3. How often did your firm (or parent company) prepare financial statements (including annual reports, 10Ks)? Please check relevant items below.
      Audited, unaudited, annual reports, 10Ks, 10Qs, Monthly, quarterly, semi-annually, annually
      4. Accounting basis: GAAP, cash, tax, or other comprehensive
    - basis of accounting (specify)

Note: The Commission may request that your company submit copies of its financial statements, including internal profit-and-loss statements for the division or product group that includes calhypo, as well as those statements and worksheets used to compile data for your firm's questionnaire response.

- III-3. <u>Cost accounting system</u>.--Briefly describe your firm's cost accounting system (*e.g.*, standard cost, job order cost, *etc.*).
- III-4. <u>Allocation basis</u>.--Briefly describe your firm's allocation basis, if any, for COGS, SG&A, and interest expense and other income and expenses.

### PART III.--<u>FINANCIAL INFORMATION</u>--Continued

III-5. <u>Other products</u>.—Please list any other products your firm produced in the facilities in which your firm produced calhypo, and provide the share of net sales accounted for by these other products in your firm's most recent fiscal year:

Products	Share of sales
	%
calhypo	
	%
	%
	%
	%

III-6. Does your firm purchase <u>inputs (raw materials, labor, energy, or any other services)</u> used in the production of calhypo <u>from any related firms</u>?

III-7. **Inputs from related firms.**--In the space provided below, identify the inputs used in the production of calhypo that your firm purchases from related parties.

Related party

III-8. <u>Inputs from related firms at cost</u>.--<u>All intercompany profit on inputs purchased from related parties</u> should be eliminated from the costs reported to the Commission in question III-10 (i.e., costs reported in question III-10 should only reflect the related party's cost and not include an associated profit component). Reasonable methods for determining and eliminating the associated profit on inputs purchased from related parties are acceptable.

Has your firm complied with the Commission's instructions regarding costs associated with inputs purchased from related parties?

Yes--Continue to question III-7 below.

No--Continue to question III-9 below.

# PART III.--FINANCIAL INFORMATION--Continued

Yes No--Please contact (202-708-4725, David.Boyland@usitc.gov).

### PART III.--<u>FINANCIAL INFORMATION</u>--Continued

III-9. Nonrecurring items (charges and gains) included in reported in calhypo financial results.--For each annual and interim period for which financial results are reported in question III-10, please specify all material (significant) nonrecurring items (charges and gains) in the schedule below, the specific table III-10 line item where the nonrecurring items are included, a brief description of the relevant nonrecurring items, and the associated values (*in \$1,000*), as reflected in table III-10; i.e., if an aggregate nonrecurring item has been allocated to table III-10, only the allocated value amount included in table III-10 should be reported in the schedule below. Note: The Commission's objective here is to gather information only on material (significant) nonrecurring items which impacted the reported calhypo financial results in table III-10.

	Fiscal years ended			January-September	
	2010	2011	2012	2012	2013
<b>Nonrecurring item:</b> In this column please provide a brief description of each nonrecurring item and indicate the specific table III-10 line item where the nonrecurring item is included.	<b>Nonrecurring item:</b> In these columns please report the amount ( <i>in \$1,000</i> ) of the relevant nonrecurring item reported in table III-10.				
1.					
2.					
3.					
4.					
5.					
6.					
7.					

### PART III.--FINANCIAL INFORMATION--Continued

III-10(a). <u>Operations on calhypo</u>.--Report the revenue and related cost information requested below on the calhypo operations of your firm's U.S. establishment(s).<sup>1</sup> Do <u>not report resales</u> of products. Note that <u>internal consumption and transfers to related firms must be valued at fair market value and purchases</u> from related firms must be at cost.<sup>2</sup> Provide data for your firm's three most recently completed fiscal years, and for the specified interim periods.

	Fiscal years ended January-September			ptember	
Item	2010	2011	2012	2012	2013
Net sales quantities: <sup>3</sup> Commercial sales ("CS")					
Internal consumption ("IC")					
Transfers to related firms ("Transfers")					
Total net sales quantities	0	0	0	0	C
Net sales values: <sup>3</sup> Commercial sales					
Internal consumption					
Transfers to related firms					
Total net sales values	0	0	0	0	C
Cost of goods sold (COGS): <sup>4</sup> Raw materials					
Direct labor					
Other factory costs					
Total COGS	0	0	0	0	C
Gross profit or (loss)	0	0	0	0	C
Selling, general, and administrative (SG&A) expenses: Selling expenses					
General and administrative expenses					
Total SG&A expenses	0	0	0	0	0
Operating income (loss)	0	0	0	0	0
Other expenses and income: Interest expense					
All other expense items					
All other income items					
Net income or (loss) before income taxes	0	0	0	0	C
Depreciation/amortization included above					

<sup>3</sup> Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

<sup>4</sup> COGS should include costs associated with CS, IC, and Transfers, as well as export shipments in question II-8.

*Note -- The table above contains calculations that will appear when you have entered data in the MS Word form fields.* 

### PART III.--<u>FINANCIAL INFORMATION</u>--Continued

III-10(b). <u>Financial data reconciliation</u>.--The calculable line items from question III-10 (*i.e.*, total net sales quantities and values, total COGS, gross profit (or loss), total SG&A, and net income (or loss)) have been calculated from the data submitted in the other line items. Do the calculated fields return the correct data according to your firm's financial records ignoring non-material differences that may arise due to rounding?

	Yes

No.--If the calculated fields do not show the correct data, please double check the feeder data for data entry errors and revise.

Also, check signs accorded to the post operating income line items; the two expense line items should report positive numbers (*i.e.*, expenses are positive and incomes or reversals are negative--instances of the latter should be rare in those lines) while the income line item also in most instances should have its value be a positive number (*i.e.*, income is positive, expenses or reversals are negative).

If after reviewing and potentially revising the feeder data your firm has provided, the differences between your records and the calculated fields persist please identify and discuss the differences in the space below.

#### PART III.--FINANCIAL INFORMATION--Continued

III-11. <u>Asset values</u>.--Report the <u>total</u> assets (i.e., both current and long-term assets) associated with the production, warehousing, and sale of calhypo. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for calhypo in the normal course of business, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with your firm's cost allocations in the previous question. Provide data as of the end of your firm's three most recently completed fiscal years.

**Note:** Total assets should reflect <u>net assets</u> after any accumulated depreciation and allowances deducted. Total assets should be <u>allocated to the subject products</u> if these assets are also related to other products. Please provide a <u>brief explanation if there are any substantial changes</u> in total asset value during the period; e.g., due to asset write-offs, revaluation, and major purchases.

Value ( <i>in \$1,000</i> )				
	Fiscal years ended			
Item	2010 2011 2012			
Total assets (net)				

III-12. <u>Capital expenditures and research and development expenses</u>.--Report your firm's capital expenditures and research and development expenses on calhypo. Provide data for your firm's three most recently completed fiscal years, and for the specified interim periods.

Value ( <i>in \$1,000</i> )					
	Fiscal years ended			January-September	
Item	2010	2011	2012	2012	2013
Capital expenditures					
Research and development expenses					

III-13. **Data consistency and reconciliation.**--Please indicate whether your firm's financial data for questions III-10, 11, and 12 are based on a calendar year or on your firm's fiscal year:

Calendar year	Fiscal year	Specify fiscal year

Please note the quantities and values reported in question III-10 should reconcile with the data reported in question II-8 (including export shipments) as long as they are reported on the same calendar year basis.

Do these data in question III-10 reconcile with data in question II-8?

Yes	No	If no, please explain.

### PART III.--FINANCIAL INFORMATION--Continued

- III-14. <u>Effects of imports</u>.--Since January 1, 2010, has your firm experienced any actual negative effects on its return on investment or its growth, investment, ability to raise capital, existing development and production efforts (including efforts to develop a derivative or more advanced version of the product), or the scale of capital investments as a result of imports of calhypo from China?
  - No Yes--My firm has experienced actual negative effects as follows:
    - Cancellation, postponement, or rejection of expansion projects
    - Denial or rejection of investment proposal
    - Reduction in the size of capital investments
    - Rejection of bank loans
    - Lowering of credit rating
    - Problem related to the issue of stocks or bonds
    - Other (specify)
- III-15. <u>Anticipated effects of imports</u>.--Does your firm anticipate any negative effects due to imports of calhypo from China?

No	Yes	If yes, my firm anticipates negative effects as follows:

### PART IV.--PRICING AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from James Fetzer (202-708-5403,james.fetzer@usitc.gov)

IV-1. <u>Contact information</u>.--Please identify the individual that Commission staff may contact regarding the confidential information submitted in part IV.

Name	
Title	
Email	
Telephone	
Fax	

## PRICE DATA

IV-2. This question requests quarterly quantity and value data, f.o.b. your firm's U.S. point of shipment, for your firm's commercial shipments to unrelated U.S. customers since January 1, 2010 of the following products produced by your firm.

Note that some or all of the products that you produce may not match these specifications. If that is the case, do not report data for these products unless the product is competitive with one of these products. However, please respond to the other questions in Part IV with respect to all your sales or use of calhypo.

<u>**Product 1.**</u>—Calcium Hypochlorite, 65%-68% available chlorine, granular, 100 lbs., however packaged, sold into the repacker/private label channel.

**<u>Product 2</u>.--** Calcium Hypochlorite, 65%-68% available chlorine, granular, 100 lbs., however packaged, sold directly to dealers that serve the private residential or commercial swimming pool channels.

Please note that total dollar values should be f.o.b., U.S. point of shipment and should not include U.S.-inland transportation costs. Total dollar values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates). See instruction booklet.

IV-2. **<u>Pricing data</u>.-**Report below the quarterly price data<sup>1</sup> for pricing products<sup>2</sup> produced and sold by your firm.

### Report data in actual pounds and actual dollars (not 1,000s).

Period of shipment	Produ Quantity			uct 2
2010:	Quantity	Malaa		
		Value	Quantity	Value
January-March				
April-June				
July-September				
October-December				
<b>2011:</b> January-March				
April-June				
July-September				
October-December				
2012:				
January-March				
April-June				
July-September				
October-December				
2013:				
January-March				
April-June				
July-September				
eturned goods), f.o.b. your <sup>2</sup> Pricing product definitio <b>lote</b> If your firm's product	firm's U.S. point of ship ons are provided on the does not exactly meet t	ment. first page of Part III. the product specificat		with the specified
product, provide a description pricing data.				
Product 1:				

IV-3. <u>Price setting</u>.-- How does your firm determine the prices that it charges for sales of calhypo (*check all that apply*)? If your firm issues price lists, please submit sample pages of a recent list.

Transaction by transaction	Set price lists	Other	lf other, describe

IV-4. **Discount policy.--** Please indicate and describe your firm's discount policies (*check all that apply*).

Quantity discounts	Annual total volume discounts	No discount policy	Other	Describe

#### IV-5. Pricing terms for calhypo.--

(a) What are your firm's typical sales terms for its U.S.-produced calhypo?

Net 30 days	Net 60 days	2/10 net 30 days	Other	Other (specify)

(b) On what basis are your firm's prices of domestic calhypo usually quoted (*check one*)?

Delivered	F.o.b.	If f.o.b., specify point

IV-6. <u>Contract versus spot</u>.--Approximately what share of your firm's sales of its U.S.-produced calhypo in 2012 was on a (1) long-term contract basis, (2) short-term contract basis, and (3) spot sales basis?

Type of sale	<u>Share o</u> 2012 sa	-
<b>Long-term contracts</b> (multiple deliveries for more than 12 months)		%
<b>Short-term contracts</b> (multiple deliveries up to and including 12 months)		%
Spot sales (for a single delivery)		%
Total	100	%

IV-7. <u>Contract provisions</u>.— Please fill out the table with respect to provisions of your firm's typical sales contracts for calhypo (or check "not applicable" if your firm does not sell on a long-term and/or short-term contract basis).

Typical sales contract provisions	ltem	Short-term contracts (multiple deliveries up to and including 12 months)	Long-term contracts (multiple deliveries for more than 12 months)
Average contract duration	Number of days		
Price renegotiation (during the	Yes		
contract period)	No		
	Quantity		
Fixed quantity and/or price	Price		
	Both		
Most or release provision	Yes		
Meet or release provision	No		
Not applicable			

IV-8. <u>Lead times</u>.--What is your firm's share of sales both from inventory and produced to order and what is the typical lead time between a customer's order and the date of delivery for your firm's sales of its U.S.-produced calhypo?

Source	<u>Share of</u> 2012 sales	<u>Lead time (days)</u>
From inventory	%	
Produced to order	%	
Total	100 %	

#### IV-9. Shipping information.--

- (a) What is the approximate percentage of the total delivered cost of calhypo that is accounted for by U.S. inland transportation costs? \_\_\_\_\_%
- (b) Who generally arranges the transportation to your firm's customers' locations? Your firm Purchaser (*check one*)
- (c) Indicate the approximate percentage of your firm's sales of calhypo that are delivered the following distances from its production facility.

Distance from production facility	Share
Within 100 miles	%
101 to 1,000 miles	%
Over 1,000 miles	%
Total	100 %

IV-10. <u>Geographical shipments</u>.-- In which U.S. geographic market area(s) has your firm sold its U.S.-produced calhypo since January 1, 2010 (check all that apply)?

Geographic area	if applicable
NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT.	
MidwestIL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	
SoutheastAL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	
Central SouthwestAR, LA, OK, and TX.	
MountainsAZ, CO, ID, MT, NV, NM, UT, and WY.	
Pacific CoastCA, OR, and WA.	
<b>Other</b> .–All other markets in the United States not previously listed, including AK, HI, PR, and VI, among others.	

IV-11. <u>End uses</u>.--List the end uses of the calhypo that your firm manufactures. For each end-use product, what percentage of the <u>total cost</u> is accounted for by calhypo and other inputs?

	Share of total cos accoun		
End use product	Calhypo (percent)	Other inputs (percent)	Total
	%	%	100%
	%	%	100%
	%	%	100%

IV-12. <u>Substitutes</u>.-- Can other products be substituted for calhypo?

🗌 No

Yes--Please fill out the table.

		End use in which this		Have changes in the prices of this substitue affected the price for calhypo?		
	Substitute	substitute is used	No	Yes	Explanation	
1.						
2.						
3.						

IV-13. <u>Demand trends</u>.-- Indicate how demand within the United States and outside of the United States (if known) for calhypo has changed since January 1, 2010. Explain any trends and describe the principal factors that have affected these changes in demand.

Market	Overall increase	No change	Overall decrease	Fluctuate with no clear trend	Explanation and factors
Within the United States					
Outside the United States					

IV-14. **Product changes.--**Have there been any significant changes in the product range, product mix, or marketing of calhypo since January 1, 2010?

No	Yes	If yes, please describe and quantify if possible.

#### IV-15. Business cycles.--

(a) Is the calhypo market subject to business cycles (other than general economy-wide conditions) and/or other conditions of competition distinctive to calhypo?

No (skip to question IV-16).

Yes-Business cycles (e.g. seasonal business).

Yes-Other distinctive conditions of competition.

If yes, describe below.

Business cycles	
Other conditions of competition	

(b) If yes, have there been any changes in the business cycles or conditions of competition for calhypo since January 1, 2010?

No	Yes	If yes, please describe.

IV-16. <u>Supply constraints</u>.--Has your firm refused, declined, or been unable to supply calhypo since January 1, 2010 (examples include placing customers on allocation or "controlled order entry," declining to accept new customers or renew existing customers, delivering less than the quantity promised, been unable to meet timely shipment commitments, etc.)?

No	Yes	If yes, please describe.

IV-17. <u>Raw materials</u>.--Please describe any trends in the prices of raw materials used to produce calhypo and whether your firm expects these trends to continue.

IV-18. **Interchangeability.--**Is calhypo produced in the United States and in other countries interchangeable (*i.e.*, can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

- A = the products from a specified country-pair are *always* interchangeable
- F = the products are *frequently* interchangeable
- S = the products are *sometimes* interchangeable
- N = the products are *never* interchangeable
- 0 = no familiarity with products from a specified country-pair

Country-pair	China	Other countries
United States		
China		
	ry-pair producing calhypo that is so ctors that limit or preclude interchan	metimes or never interchangeable, please geable use:
		<u>.</u>

IV-19. <u>Factors other than price</u>.--Are differences other than price (*i.e.*, quality, availability, transportation network, product range, technical support, *etc.*) between calhypo produced in the United States and in other countries a significant factor in your firm's sales of the products?

Please indicate A, F, S, N, or 0 in the table below:

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N = such differences are *never* significant

0 = no familiarity with products from a specified country-pair

Country-pair	China	Other countries
United States		
China		
factor in your firm		ice always or frequently are a significant untry-pair and report the advantages or

#### **Business Proprietary**

# PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-20. Customer Identification--Please identify the names and contact information for your firm's 10 largest U.S. customers for calhypo since January 1, 2010. Indicate the share of the quantity of your firm's total shipments of calhypo that each of these customers accounted for in 2012.

Cı	ustomer's name	Contact person Email		Telephone	Street address (not P.O. box), city, state, and zip code	Share of 2012 sales (%)
1					Street Address , City State Zip Code	
2					Street Address City State Zip Code	
3					Street Address City State Zip Code	
4					Street Address City State Zip Code	
5					Street Address City State Zip Code	
6					Street Address City State Zip Code	
7					Street Address City State Zip Code	
8					Street Address City State Zip Code	
9					Street Address , City State Zip Code	
10					Street Address City State Zip Code	

#### IV-21. Competition From Imports--Lost Revenue.--

Since January 1, 2010: To avoid losing sales to competitors selling calhypo from China, did your firm:

Reduce prices Roll back announced price increases

No	Yes

**The table below is to be completed only by NON-PETITIONERS.** (Note: petitioners may provide allegations involving quotes made AFTER the filing of the petition.)

If you indicated "yes" above, please furnish the following information for each affected transaction. If possible, provide documentation (e.g., copies of invoices, sales reports, or letters from customers). Please note that the Commission may contact the firms named to verify the allegations reported.

Customer name, contact person, phone and fax numbers Specific product(s) involved Date of your firm's initial price quotation Quantity involved Your firm's initial *rejected* price quotation (total delivered value) Your firm's *accepted* price quotation (total delivered value) The country of origin of the competing imported product The competing price quotation of the imported product (total delivered value)

Customer nam contact persor phone and fax numbers	n,	Product	Country of origin	Date of quote	Quantity ( <i>pounds</i>	Initial rejected U.S. price (total value <i>dollars</i> )	Accepted U.S. price (total value <i>dollars</i> )	Competing import price (total value— <i>dollars</i> )
Firm								
Contact								
Phone Fax								
Firm								
Contact								
Phone Fax								
Firm								
Contact								
Phone Fax								
Firm								
Contact								
Phone Fax								

#### IV-22. Competition From Imports--Lost Sales.-

Since January 1, 2010: Did your firm lose sales of calhypo to imports of these products from China?

No	Yes

**The table below is to be completed only by NON-PETITIONERS.** (Note: petitioners may provide allegations involving quotes made AFTER the filing of the petition.

If you indicated "yes" above, please furnish the following information for each affected transaction. If possible, provide documentation (e.g., copies of invoices, sales reports, or letters from customers). Please note that the Commission may contact the firms named to verify the allegations reported.

Customer name, contact person, phone and fax numbers Specific product(s) involved Date of your firm's price quotation Quantity involved Your firm's rejected price quotation (total delivered value) The country of origin of the competing imported product The accepted price quotation of the imported product (total delivered value)

Customer name, contact person, phone and fax numbers	Product	Country of origin	Date of quote	Quantity ( <i>pounds</i> )	Rejected U.S. price (total value <i>dollars</i> )	Competing import price (total value— dollars)
Firm						
Contact						
Phone Fax						
Firm						
Contact						
Phone Fax						
Firm						
Phone Fax						
Firm Contact						
Phone Fax						